Floatz logo

BMS 986253

Antineoplastic Agents

Yana Najjarmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Antineoplastic Agents cohort.

Asset / SponsorPhaseRating
Zofran
Dr Atul Sharma
Phase 3BB
(+)-VINCRISTINE
Instituto do Cancer do Estado de São Paulo
Phase 3BB
TRASTUZUMAB
Incepta Pharmaceuticals Ltd
Phase 2BB
Cetuximab
Armando Orlandi
Phase 3B
Abemaciclib
Eli Lilly and Company
Phase 3B

View all 25 →

Same molecule, other indications

BMS 986253 is also rated in:

colon carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
COVID-19Dormant
CCC
Indicative ·
53 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →